Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, One-Way, Crossover, Drug-Drug Interaction Study Assessing the Effect of Mefenamic Acid on the Pharmacokinetics (PK) of Epacadostat in Healthy Volunteers

Trial Profile

A Phase I, Open-Label, One-Way, Crossover, Drug-Drug Interaction Study Assessing the Effect of Mefenamic Acid on the Pharmacokinetics (PK) of Epacadostat in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2018

At a glance

  • Drugs Epacadostat (Primary) ; Mefenamic acid
  • Indications Colorectal cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Urogenital cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Sep 2018 New trial record
    • 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development Journal: 2018 Annual Meeting of the American College of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top